NCT00698061已完成3 期
A Study to Compare the Immunogenicity and Safety of GSK Biologicals Adjuvanted HBV Vaccine to Engerix™-B, in a Non-responder Population ≥ 15 Years of Age, When Administered Intramuscularly, According to a 0, 1, 2, 12 Month Schedule
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 145
- 主要终点
- Anti-HBs antibody concentrations
研究概览
简要总结
Subjects who had not responded to previous hepatitis B vaccination were vaccinated with either the adjuvanted HBV-MPL vaccine or Engerix™-B vaccine according to a three-dose vaccination schedule (0, 1, 2 months) and boosted at Month 12 as per their group allocation. The immunogenicity and safety of the HBV-MPL vaccine were compared with the control vaccine, Engerix™-B.
详细描述
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •At study entry:
- •A male or female ≥ 15 years of age at the time of the first vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Written informed consent obtained from the subject.
- •Documented non-response to previous hepatitis B vaccination within 6 months after having received a full vaccination course (i.e. ≥ 3 doses of a hepatitis B vaccine)
- •If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination.
- •Before booster dose at month 12:
- •Additional written informed consent covering the booster administration and blood samples at months 12 and 13 must be obtained from the subject.
- •If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to and up to two months after the administration of the booster dose
排除标准
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
- •Known exposure to hepatitis B within 6 weeks.
- •History of hepatitis B infection.
- •Confirmed human immunodeficiency virus (HIV) infection.
- •A family history of congenital or hereditary immunodeficiency.
- •History of allergic disease/reactions likely to be exacerbated by any component of the vaccine.
- •Acute disease at the time of enrollment.
- •Hepatomegaly, right upper quadrant abdominal pain or tenderness.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration/ administration during the study period.
- •Pregnant or lactating female.
结局指标
主要结局
Anti-HBs antibody concentrations
时间窗: Months 1, 2 and 3
次要结局
- Occurrence, intensity and relationship to vaccination of solicited local and general signs and symptoms(During a 4 day follow-up period after vaccination)
- Occurrence, intensity and relationship to vaccination of unsolicited signs and symptoms(During a 30 day follow-up period after vaccination)
- Occurrence, intensity and relationship to vaccination of serious adverse events (SAEs)(During the study period, up to and including 6 months post-vaccination)
- Anti-HBs antibody concentrations in all subjects(Months 1, 2, 3, 12 and 13)
研究者
相似试验
已完成
不适用
Study on New Strategies for Hepatitis B Virus ImmunizationVaccine ReactionNCT06515938Wu Jiang1,169
已完成
3 期
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older AdultsHepatitis BNCT00697242GlaxoSmithKline362
Unknown
4 期
Twinrix Alternative Schedule StudyAntibody Response After VaccinationNCT00216229IDEWE Occupational Health Services400
已完成
3 期
Responsiveness to the hepatitis B vaccine in Autistic childAutism.Childhood autismIRCT20130904014562N2Tehran University of Medical Sciences105
已完成
不适用
A study to determine the optimum timing of Hepatitis B vaccination during treatment of Acute Lymphoblastic leukemia( a type of blood cancer)CTRI/2017/08/009402JIPMER58